You just read:

XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome

News provided by

XTL Biopharmaceuticals Ltd

Apr 05, 2017, 09:10 ET